BioSpace News Archive

Hutchison China MediTech Limited announces that Elunate®, its national class 1 targeted anticancer drug for the treatment of patients with advanced colorectal cancer, has been included in the updated National Reimbursement Drug List released by China’s National Healthcare Security Administration.

Concord Medical Services Holdings Limited, a specialty hospital management group and an operator of the network of radiotherapy and diagnostic imaging centers in China, announced that it will hold its 2019 annual general meeting of shareholders on December 27, 2019, at 10:00 a.m.

Antibe Therapeutics Inc., a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended September 30, 2019.

Pharmaron Beijing Co., Ltd. announced that 117 million H-shares are listed on the Main Board of The Stock Exchange of Hong Kong.

Genetron Health, a China-based precision oncology company that covers full-cycle cancer care, has obtained regulatory approval in China to launch its GENETRON S5 for clinical use.

Satralizumab added to baseline immunosuppressant therapy significantly reduced risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).

Data show patients had a 50% reduction in risk of recurrence compared to treatment with Herceptin® (trastuzumab) after surgery2

Ascletis Pharma Inc. announces that Ascletis XinNuo Medicine Co.,Ltd., a wholly-owned subsidiary of Ascletis, has recently obtained the Pharmaceutical Trade License and GSP Certificate issued by ZheJiang Medical Products Administration.

Liminal BioSciences Inc. acknowledges the press release issued by the Autorité des Marchés Financiers in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019.